IceCure Medical Ltd. announced the latest release of a study (the "Study") in a series of independent studies of ProSense®? published in peer-reviewed journals demonstrating safety and efficacy. The Study, titled "Single-Probe Percutaneous Cryoablation with Liquid Nitrogen for the Treatment of T1a Renal Tumors", published in Cancers, demonstrated the safety and efficacy of ProSense®?

in treating malignant small renal masses. The Study was authored by eight physicians in France, including interventional radiologists and neurologists from Curie Institute, Paris, Nimes University Hospital (University of Montpellier), Nimes, and Caremeau University Hospital, Nimes. This technology stands out as a forward-thinking solution in oncological treatment, providing a combination of patient safety, procedural efficiency, and cost-effectiveness.